|Day Low/High||0.46 / 0.50|
|52 Wk Low/High||0.44 / 4.75|
Hedge fund manager Gregory Taxin of Clinton Group talks about when companies hit a critical point that makes them ripe for activism.
Obesity costs are a pain point, which often create good investments.
Here is this week's roundup of the dumbest actions on Wall Street.
Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.
Jim Cramer says we should throw out the ADP report and the BLS should out source the work to TIBCO.
Mike MacDonald, CEO of Medifast, says the company's new franchise strategy is propelling its stock and recently approved weight loss pills are not a threat.
Senior columnist Adam Feuerstein says obesity drugs are the next big thing to watch in biotech.
Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.
Adam Feuerstein, senior columnist for TheStreet, says Vivus is the next big thing in biotech.
The longer this action persists, the more anxious folks will be to put idle cash to work.